DEA Judge Orders 294 Fixes to Cannabis Rescheduling Transcript

August 24, 2026

Photo via Unsplash.

Derek C. Julius, the DEA's chief administrative law judge, has ordered nearly 300 corrections to the transcript from this summer's marijuana rescheduling hearing before the record can go public. The hearing itself ran 11 days and wrapped up July 15 in Arlington, Virginia, generating roughly 2,500 pages of testimony, cross-examination and legal argument over whether cannabis should move from Schedule I to Schedule III of the Controlled Substances Act. Now that transcript needs cleanup: 294 corrections, marked in red text with strikethroughs showing what's been deleted, all due for public posting by August 26, 2026.

It's a bureaucratic housekeeping step, the kind of thing that normally wouldn't rate a headline. But this is the record that will underpin whatever recommendation Julius eventually sends up the chain at DEA, and in a proceeding this contentious, even a flipped word can matter. After years of delays, lawsuits and shifting political winds around rescheduling, the fight has come down to something as unglamorous as fixing typos in a hearing transcript -- and that's worth understanding in detail.

What the Correction Order Actually Says

Photo via Unsplash.

The order itself landed on Thursday, August 20, 2026, and runs 13 pages -- a fairly detailed document for what is, on its face, an administrative cleanup task. Julius gave the DEA and the seven parties opposing rescheduling until August 17 to comb through the transcript and flag anything wrong: misattributed quotes, garbled transcription, misspelled names, that sort of thing. What came back was a list of 294 requested corrections spread across roughly 2,500 pages of testimony and argument from the July hearing.

Procedurally, the fixes will show up as red text in the electronic version of the transcript, with strikethroughs marking whatever gets deleted or replaced. That's standard practice for court and administrative reporters -- it lets anyone reviewing the record see exactly what changed and why, rather than quietly swapping in a clean copy. Before the corrected transcript goes live, DEA will also strip out personally identifiable information, which is routine for hearings involving expert witnesses, medical professionals and others who may have disclosed personal details in testimony.

None of this is unusual for a proceeding of this length and complexity. Eleven days of hearing testimony, with multiple witnesses, attorneys and a judge all talking over a court reporter trying to keep pace, is going to generate transcription errors. What makes this instance notable is simply the scale of scrutiny both sides are applying to a record that could shape federal drug policy for years.

Small Words, Big Stakes: The Substantive Fixes

Photo by cottonbro studio via Pexels.

Most of the 294 corrections are exactly what you'd expect: misspelled names, dropped words, minor punctuation fixes that don't change meaning. But a handful of them are the kind of errors that could genuinely distort the record if left uncorrected -- and that's presumably why both DEA and the opposing parties took the review process seriously enough to generate a 13-page order.

One correction takes a witness statement that originally read as a declarative sentence -- This is a medication -- and turns it into a question: This is a medication? That's not a cosmetic change. A statement and a question convey opposite postures toward the same subject matter, and in a hearing where witness credibility and the substance of their testimony carry real weight, mixing up one for the other could misrepresent what was actually said on the stand.

Another correction is even more consequential: fixing there's adulterants to there's no adulterants. That single dropped word inverts the entire meaning of the statement. Whether a witness testified that a product contains contaminants or that it doesn't is the kind of detail that could matter enormously if cited later in briefing or in Julius's eventual recommendation.

These aren't hypothetical concerns. The transcript isn't just a courtesy record -- it's the evidentiary foundation Julius will rely on when he writes his recommendation to DEA leadership, and it's also what the opposing parties will cite in their exceptions and findings of fact. A transcription error that survives uncorrected into a final recommendation could end up shaping how regulators, courts or future litigants understand what actually happened at the hearing.

The Underlying Fight Over Rescheduling

Photo by Gabrigel via Unsplash.

The hearing that produced this transcript exists because DEA, under a Biden-era proposal, moved to reclassify marijuana from Schedule I to Schedule III -- a shift that would acknowledge accepted medical use and lower abuse potential relative to drugs like heroin. That proposal didn't go unchallenged. Seven parties opposed to rescheduling used the 11-day hearing as their venue to contest it, including an anti-legalization advocacy group, the states of Idaho, Indiana and Nebraska, the Texas Board of Innkeeping's regulatory counterpart known as TBI, and the National Drug and Alcohol Screening Association.

Their core argument centers on methodology. Historically, drug scheduling decisions relied on a five-factor test to assess medical acceptance and abuse potential. Opponents argue DEA improperly substituted a narrower two-part test to evaluate cannabis, and that under the traditional standard, marijuana still doesn't meet the bar for accepted medical value. It's a technical argument, but a consequential one -- if the test itself was applied incorrectly, that could undercut the entire rescheduling proposal regardless of what the underlying science shows.

DEA's final brief pushed back directly, arguing that current evidence supports both an accepted medical use for marijuana and accepted safety when used under medical supervision -- the two conditions that matter most for placement in Schedule III rather than Schedule I. Both sides filed their final briefs around August 17 and 18, 2026, essentially bookending the same window when transcript corrections were being finalized. The timing isn't coincidental; both processes are converging toward the same next step in the proceeding.

What Happens After the Transcript Is Finalized

Photo by Towfiqu barbhuiya via Pexels.

Once the corrected transcript is posted publicly -- no later than August 26, 2026, per Julius's order -- the next move belongs to the judge himself. He's expected to issue a recommendation on marijuana's appropriate scheduling status based on the hearing record, the briefs and the corrected transcript now locked into the docket.

That's not the end of the road, though. Designated parties will get 20 days after Julius's recommendation to file exceptions, along with their own proposed findings of fact and conclusions of law. That's a standard step in administrative proceedings, giving both sides one more formal chance to argue over specifics before the record heads further up the chain.

Outside observers tracking the case have generally suggested the whole process could stretch on for weeks or realistically months beyond the transcript's finalization, with many now expecting a recommendation sometime in late 2026 rather than sooner. Given how many procedural steps remain -- exceptions, findings, and eventually a decision from DEA leadership -- that timeline feels plausible rather than pessimistic.

Worth remembering here: none of this changes what's legal where you live today. Cannabis laws vary enormously from state to state regardless of what happens at the federal scheduling level, and that patchwork isn't going away just because DEA eventually rules one way or another. Anyone making decisions based on legality -- whether you're a patient, a grower or a business owner -- should confirm the current rules in your own state rather than assuming federal rescheduling will resolve anything locally.

Rescheduling Ripples Across the States

While DEA works through transcript corrections and legal briefs in Washington, state-level cannabis and hemp policy keeps moving on its own timeline, and in some cases the stakes are just as high. In South Dakota, the administrator overseeing the state's medical marijuana program has said federal officials still haven't clarified how rescheduling would actually affect state-run programs -- leaving state regulators to plan in the dark for a policy shift they can't yet predict.

Tennessee is facing a different kind of fallout: a projected $110 million tax shortfall tied directly to the state's ban on hemp-derived products. That's real money missing from state coffers because of a policy choice made independent of anything happening at DEA.

Texas has its own mess brewing. A lawsuit challenging the state's hemp THC restrictions is moving forward, with businesses in the industry citing more than 36,000 lost jobs and a retail sales drop exceeding 50 percent since the restrictions took hold. Those are the kinds of numbers that tend to get attention from state legislators regardless of which way federal scheduling eventually breaks.

Meanwhile in Michigan, gubernatorial candidate John James has staked out a policy position combining a cut to the marijuana wholesale tax with tighter restrictions on hemp-derived THC products -- a split approach that reflects how differently state politicians are treating the two categories even as federal rescheduling debates lump them together in the public conversation.

Taken together, these state fights underscore something easy to miss while watching the DEA docket: federal rescheduling is one piece of a much larger, messier policy landscape that states are actively reshaping on their own, with real economic consequences already showing up in tax revenue, job numbers and retail sales.

Spending a 13-page order fixing 294 corrections across a 2,500-page transcript isn't glamorous, but it's an honest snapshot of where this process actually sits right now. This isn't a political fight playing out in press conferences -- it's a procedural grind through hearing records, briefing schedules and administrative deadlines, the unglamorous machinery that has to run its course before anything resembling a final decision gets made.

It's also worth keeping expectations calibrated. Whatever recommendation Judge Julius eventually issues won't bind DEA leadership to act on it. The agency retains final authority over where marijuana ends up on the schedule, and history is full of examples where administrative recommendations didn't translate cleanly into agency action. So even a favorable recommendation for rescheduling advocates wouldn't guarantee an outcome -- it would just be the next data point in a longer process.

In the meantime, the more immediately consequential action for patients and businesses is happening at the state level. Texas's THC lawsuit, Tennessee's revenue shortfall, South Dakota's regulatory uncertainty -- these are live issues with real economic and legal consequences unfolding right now, independent of whatever timeline DEA eventually follows. Anyone with skin in this industry should be watching both tracks, because state rules aren't waiting around for Washington to finish correcting its transcript.